North America Skin Cancer Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Melanoma and Non-Melanoma) and Screening Type (Blood Tests, Dermatoscopy, Imaging Tests, Lymph Node Biopsy, and Skin Biopsy)
The North America skin cancer diagnostics market is expected to reach US$ 2,354.2 million by 2028 from US$ 1,423.0 million in 2021; it is estimated to grow at a CAGR of 7.5% from 2021 to 2028.
Breast, lung, colon and rectum, prostate, skin, and stomach cancer were very common in this region. According to the WHO data, ~1.20 million of the new cases reported in 2020 were skin cancer cases. Skin cancer is by far the most common of all cancer types. Melanoma and non-melanoma are the two types of skin cancer. Although melanoma accounts for ~1% of total skin cancer cases, it causes maximum skin cancer deaths. The incidence rate of melanoma rapidly increased in the past few decades, and it also varies with age. According to the American Cancer Society, the US's annual new cancer diagnoses count is likely to reach ~99,780 cases in 2022; out of these, 57,180 patients are likely to be men, and 42,600 would be women. It further states that 7,650 people are expected to die due to melanoma (5,080 men and 2,570 women). According to the Skin Cancer Foundation, during 2012–2022, annual diagnosis for invasive melanoma cases increased by 31%. Thus, the incidence of skin cancer is likely to increase in the coming years leading to higher demand for skin cancer diagnostics.
With the new features and technologies, vendors attract new customers and expand their footprints in emerging markets. This factor is driving the growth of the skin cancer diagnostics market at a promising CAGR.
North America Skin Cancer Diagnostics Market Revenue And Forecast To 2028 (US$ Million)
Get more information on this report :
The skin cancer diagnostics market is segmented into type and screening type. Based on type, the market is segmented into melanoma and non-melanoma. Based on screening type, the market is segmented into skin biopsy, dermatoscopy, lymph node biopsy, imaging tests, and blood tests. Based on country, the market is segmented into the US, Canada, and Mexico.
SkylineDx BV; AMLo Biosciences Limited; DermLite LLC; bioMerieux SA; Veriskin Inc.; Castle Biosciences, Inc.; DermTech Inc.; F. Hoffmann-La Roche Ltd.; and Michelson Diagnostics Ltd. are among the leading companies in the North America skin cancer diagnostics market.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Skin Cancer Diagnostics Market – By Type
1.3.2 North America Skin Cancer Diagnostics Market – By Screening Type
1.3.3 North America Skin Cancer Diagnostics Market – By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Skin Cancer Diagnostics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America– PEST Analysis
4.3 Expert Opinion
5. Skin Cancer Diagnostics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Incidence of Skin Cancer
5.1.2 Launch of New Skin Cancer Diagnostics Products
5.2 Market Restraints
5.2.1 Barriers to Early Skin Cancer Diagnostics in Low and Middle-Income Countries
5.3 Market Opportunities
5.3.1 Government Support for Early Skin Cancer Diagnosis
5.4 Future Trends
5.4.1 Skin Cancer Diagnostics Through AI
5.5 Impact Analysis
6. Skin Cancer Diagnostics Market – North America Analysis
6.1 North America Skin Cancer Diagnostics Market Revenue Forecast and Analysis
7. Skin Cancer Diagnostics Market Analysis – By Type
7.1 Overview
7.2 Skin Cancer Diagnostics Market Revenue Share, by Type (2020 and 2028)
7.3 Melanoma
7.3.1 Overview
7.3.2 Melanoma: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Non-melanoma
7.4.1 Overview
7.4.2 Non-melanoma: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8. Skin Cancer Diagnostics Market – By Screening Type
8.1 Overview
8.2 Skin Cancer Diagnostics Market, by Screening Type, 2020 and 2028 (%)
8.3 Blood Tests
8.3.1 Overview
8.3.2 Blood Tests: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Dermatoscopy
8.4.1 Overview
8.4.2 Dermatoscopy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Imaging Tests
8.5.1 Overview
8.5.2 Imaging Tests: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Lymph Node Biopsy
8.6.1 Overview
8.6.2 Lymph Node Biopsy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Skin Biopsy
8.7.1 Overview
8.7.2 Skin Biopsy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9. Skin Cancer Diagnostics Market – Regional Analysis
9.1 North America: Skin Cancer Diagnostics Market
9.1.1 Overview
9.1.2 North America: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.3 North America: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.1.4 North America: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ Million)
9.1.5 North America: Skin Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
9.1.5.1 US: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.5.1.1 US: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.5.1.2 US: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.1.5.1.3 US: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ ‘Million)
9.1.5.2 Canada: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.5.2.1 Canada: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.5.2.2 Canada: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.1.5.2.3 Canada: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ ‘Million)
9.1.5.3 Mexico: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.5.3.1 Mexico: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
9.1.5.3.2 Mexico: Skin Cancer Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)
9.1.5.3.3 Mexico: Skin Cancer Diagnostics Market, by Screening Type, 2019–2028 (US$ ‘Million)
10. Skin Cancer Diagnostic Market–Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Skin Cancer Diagnostic Market (%)
10.3 Organic Developments
10.3.1 Overview
10.4 Inorganic Developments
10.4.1 Overview
11. Company Profiles
11.1 SkylineDx BV
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 SWOT Analysis
11.1.5 Key Developments
11.2 AMLo Biosciences Limited
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 SWOT Analysis
11.2.5 Key Developments
11.3 DermLite LLC
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 bioMerieux SA
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Veriskin Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Castle Biosciences, Inc.
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 DermTech Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 HOFFMANN-LA ROCHE LTD.
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.9 Michelson Diagnostics Ltd.
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
LIST OF TABLES
Table 1. North America: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 2. North America: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. US: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 4. US: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 5. Canada: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 6. Canada: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 7. Mexico: Skin Cancer Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 8. Mexico: Skin Cancer Diagnostics Market, by Screening Type – Revenue and Forecast to 2028 (US$ ‘Million)
Table 9. Organic Developments in the Skin Cancer Diagnostic Market
Table 10. Inorganic Developments in the Skin Cancer Diagnostics Market
Table 11. Glossary of Terms, Skin Cancer Diagnostics Market
LIST OF FIGURES
Figure 1. Skin Cancer Diagnostics Market Segmentation
Figure 2. North America Skin Cancer Diagnostics Market Overview
Figure 3. Non-Melanoma Segment Held Largest Share of Type Segment in Skin Cancer Diagnostics Market
Figure 4. US is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. North America Skin Cancer Diagnostics Market, Industry Landscape
Figure 6. North America PEST Analysis
Figure 7. Skin Cancer Diagnostics Market Impact Analysis of Driver and Restraints
Figure 8. North America Skin Cancer Diagnostics Market– Revenue Forecast and Analysis – 2020- 2028
Figure 9. Skin Cancer Diagnostics Market Revenue Share, by Type (2020 and 2028)
Figure 10. Melanoma: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 11. Non-melanoma: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Skin Cancer Diagnostics Market, by Screening Type, 2020 and 2028 (%)
Figure 13. Blood Tests: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Dermatoscopy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Imaging Tests: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Lymph Node Biopsy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Skin Biopsy: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. North America: Skin Cancer Diagnostics Market, by Key Country – Revenue (2021) (US$ ‘Million)
Figure 19. North America: Skin Cancer Diagnostics Market Revenue and Forecast to 2028 (US$ ‘Million)
Figure 20. North America: Skin Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
Figure 21. US: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 22. Canada: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 23. Mexico: Skin Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)
Figure 24. Growth Strategies in the Skin Cancer Diagnostic Market (%)
- SkylineDx BV
- AMLo Biosciences Limited
- DermLite LLC
- F. HOFFMANN-LA ROCHE LTD
- bioMerieux SA
- Veriskin Inc.
- Castle Biosciences, Inc.
- DermTech Inc
- ACS Dobfar S.p.A
- Michelson Diagnostics Ltd.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America skin care diagnostics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America skin care diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.